CLS Holdings USA (XCNQ:CLSH) Debt-to-Equity

: -0.88 (As of Feb. 2024)

View and export this data going back to 2019. Start your Free Trial

CLS Holdings USA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$2.72 Mil. CLS Holdings USA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$9.60 Mil. CLS Holdings USA's Total Stockholders Equity for the quarter that ended in Feb. 2024 was C$-14.01 Mil. CLS Holdings USA's debt to equity for the quarter that ended in Feb. 2024 was -0.88.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CLS Holdings USA's Debt-to-Equity or its related term are showing as below:

XCNQ:CLSH' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.54 Med: -0.79 Max: 0.82
Current: -0.88

During the past 11 years, the highest Debt-to-Equity Ratio of CLS Holdings USA was 0.82. The lowest was -3.54. And the median was -0.79.

XCNQ:CLSH's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs XCNQ:CLSH: -0.88

CLS Holdings USA Debt-to-Equity Historical Data

The historical data trend for CLS Holdings USA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CLS Holdings USA Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Debt-to-Equity

Get a 7-Day Free Trial

0.74

-3.54

-1.48

-1.51

-1.09

CLS Holdings USA Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															-1.57	-1.09	-1.00	-0.97	-0.88

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CLS Holdings USA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CLS Holdings USA Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, CLS Holdings USA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CLS Holdings USA's Debt-to-Equity falls into.

CLS Holdings USA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CLS Holdings USA's Debt to Equity Ratio for the fiscal year that ended in May. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.414	+	10.18)	/	-17.111
	=	-1.09

CLS Holdings USA's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.72	+	9.604)	/	-14.006
	=	-0.88

CLS Holdings USA (XCNQ:CLSH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CLS Holdings USA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CLS Holdings USA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CLS Holdings USA (XCNQ:CLSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CLS Holdings USA Inc (XCNQ:CLSH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CLSH:USA

Address

1800 Industrial Road, Suite 100, Las Vegas, NV, USA, 89102

Website

https://www.clsholdingsinc.com

CLS Holdings USA Inc is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada and plans to expand to other states. CLS stands for Cannabis Life Sciences in recognition of the company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services. The company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products.